EGFR and non-small cell lung carcinoma: Although most patients in this group were stage IIIB, it was also in line with a multi-center and retrospective study of unresectable advanced NSCLC with EGFR mutation, which revealed that radiotherapy combined with EGFR-RKI could prolong PFS by 21.6 months and OS by 67.4 months when compared with the chemoradiotherapy group and the EGFR-TKI alone group [29].